$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

$jrss Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417027058 Filed on May 15, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q4
Revenue	$5.358M	$5.511M	$5.160M
YoY Change	24.9%	25.0%	35.43%
Cost Of Revenue	$1.580M	$1.650M	$1.510M
YoY Change	42.34%	49.2%	49.5%
Gross Profit	$3.780M	$3.860M	$3.650M
YoY Change	18.5%	16.89%	30.36%
Gross Profit Margin	70.54%	70.05%	70.74%
Selling, General & Admin	$950.0K	$830.0K	$800.0K
YoY Change	13.1%	13.7%	26.98%
% of Gross Profit	25.13%	21.5%	21.92%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$311.4K	$303.0K	$300.0K
YoY Change	19.75%	26.1%	25.0%
% of Gross Profit	8.24%	7.85%	8.22%
Operating Expenses	$2.120M	$1.980M	$1.960M
YoY Change	26.19%	23.75%	38.03%
Operating Profit	$1.323M	$1.592M	$1.690M
YoY Change	-12.4%	17.02%	22.46%
Interest Expense	$339.4K	$289.9K	-$350.0K
YoY Change	-196.96%	-15.67%	2.94%
% of Operating Profit	25.66%	18.22%	-20.71%
Other Income/Expense, Net	-$17.33K	-$2.930K	$0.00
YoY Change		-330.89%
Pretax Income	$1.305M	$1.589M	$1.340M
YoY Change	13.52%	16.7%	28.85%
Income Tax	$716.00	$919.00	$0.00
% Of Pretax Income	0.05%	0.06%	0.0%
Net Earnings	$913.3K	$1.111M	$920.0K
YoY Change	15.61%	18.21%	29.58%
Net Earnings / Revenue	17.04%	20.17%	17.83%
Basic Earnings Per Share
Diluted Earnings Per Share	$54.49K	$66.47K	$55.09K
COMMON SHARES
Basic Shares Outstanding	13.92M shares	13.92M shares	13.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$620.0K	$250.0K	$890.0K
YoY Change	-27.06%	-39.02%	154.29%
Cash & Equivalents	$617.2K	$245.4K	$890.7K
Short-Term Investments
Other Short-Term Assets	$430.0K	$730.0K	$580.0K
YoY Change	-66.67%	-47.48%	123.08%
Inventory	$830.0K	$834.8K	$801.2K
Prepaid Expenses		$398.3K	$518.7K
Receivables	$3.710M	$3.345M	$3.336M
Other Receivables	$4.450M	$3.149K	$1.555K
Total Short-Term Assets	$10.04M	$9.564M	$7.418M
YoY Change	63.78%	57.04%	76.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.38M	$23.96M	$23.27M
YoY Change	9.68%	6.88%	3.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$940.0K	$740.0K	$1.010M
YoY Change	-13.76%	-30.84%	-6.48%
Total Long-Term Assets	$26.32M	$24.70M	$24.28M
YoY Change	8.58%	5.11%	3.22%
TOTAL ASSETS
Total Short-Term Assets	$10.04M	$9.564M	$7.418M
Total Long-Term Assets	$26.32M	$24.70M	$24.28M
Total Assets	$36.36M	$34.27M	$31.70M
YoY Change	19.72%	15.8%	14.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.180M	$1.415M	$743.7K
YoY Change	268.75%	194.69%	110.79%
Accrued Expenses	$60.00K	$60.00K	$50.00K
YoY Change	20.0%	20.0%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$540.0K	$420.8K	$0.00
YoY Change	-28.95%	-19.07%
Long-Term Debt Due	$1.200M	$2.200M	$2.310M
YoY Change	0.84%	15.18%	22.87%
Total Short-Term Liabilities	$3.390M	$4.245M	$3.218M
YoY Change	44.26%	41.48%	30.77%
LONG-TERM LIABILITIES
Long-Term Debt	$18.10M	$16.70M	$16.80M
YoY Change	2.14%	-6.02%	-5.94%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$18.10M	$16.70M	$16.80M
YoY Change	-1.25%	-6.02%	-5.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.390M	$4.245M	$3.218M
Total Long-Term Liabilities	$18.10M	$16.70M	$16.80M
Total Liabilities	$27.51M	$20.94M	$20.02M
YoY Change	9.56%	-15.99%	-1.52%
SHAREHOLDERS EQUITY
Retained Earnings		$7.386M	$6.274M
YoY Change			123.9%
Common Stock		$1.146M	$1.146M
YoY Change			0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.850M	$7.764M	$6.634M
YoY Change
Total Liabilities & Shareholders Equity	$36.36M	$34.27M	$31.70M
YoY Change	19.72%	15.8%	14.3%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q4
OPERATING ACTIVITIES
Net Income	$913.3K	$1.111M	$920.0K
YoY Change	15.61%	18.21%	29.58%
Depreciation, Depletion And Amortization	$311.4K	$303.0K	$300.0K
YoY Change	19.75%	26.1%	25.0%
Cash From Operating Activities	$1.660M	$216.0K	$1.080M
YoY Change	-19.81%	-84.0%	-1.82%
INVESTING ACTIVITIES
Capital Expenditures	-$350.0K	$373.1K	-$130.0K
YoY Change	-79.29%	428.71%	-90.71%
Acquisitions
YoY Change
Other Investing Activities	-$1.140M		-$570.0K
YoY Change			-5800.0%
Cash From Investing Activities	-$1.480M	-$591.8K	-$690.0K
YoY Change	-12.43%	-49.85%	-50.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	200.0K	-$272.4K	-30.00K
YoY Change	233.33%	172.43%	-108.57%
NET CHANGE
Cash From Operating Activities	1.660M	$216.0K	1.080M
Cash From Investing Activities	-1.480M	-$591.8K	-690.0K
Cash From Financing Activities	200.0K	-$272.4K	-30.00K
Net Change In Cash	380.0K	-$648.3K	360.0K
YoY Change	-13.64%	-1026.08%	500.0%
FREE CASH FLOW
Cash From Operating Activities	$1.660M	$216.0K	$1.080M
Capital Expenditures	-$350.0K	$373.1K	-$130.0K
Free Cash Flow	$2.010M	-$157.2K	$1.210M
YoY Change	-46.54%	-112.28%	-51.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3345358	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	23352	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	6634335	USD
CY2017Q1	us-gaap	Minority Interest MinorityInterest	5557232	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16097	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	530474	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	27322	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56309	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74585	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	890662	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23962577	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	518722	USD
CY2017Q1	us-gaap	Assets Assets	34265536	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	801240	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	846101	USD
CY2016Q4	us-gaap	Assets Assets	31702590	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1414502	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	743660	USD
CY2017Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	5796	USD
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1555	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	245387	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3335500	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	23274180	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	834788	USD
CY2017Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3149	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	398338	USD
CY2017Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4408193	USD
CY2016Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1804987	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	9563632	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	7417633	USD
CY2017Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	589738	USD
CY2016Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	5751	USD
CY2017Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	121757	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	25329	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	2313038	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4244543	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	77973	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	57786	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	52072	USD
CY2017Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	2200521	USD
CY2017Q1	us-gaap	Professional Fees ProfessionalFees	13762	USD
CY2016Q4	us-gaap	Deferred Costs DeferredCosts	164676	USD
CY2017Q1	us-gaap	Deferred Costs DeferredCosts	149589	USD
CY2016Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	574921	USD
CY2017Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	569294	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1925675	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2982737	USD
CY2016Q1	us-gaap	Professional Fees ProfessionalFees	4423	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5510812	USD
CY2016Q1	us-gaap	Depreciation Depreciation	240285	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1650466	USD
CY2016Q1	us-gaap	Supplies Expense SuppliesExpense	81806	USD
CY2017Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	21480	USD
CY2016Q1	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	389760	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6274052	USD
CY2017Q1	us-gaap	Depreciation Depreciation	303001	USD
CY2016Q1	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	9571	USD
CY2017Q1	us-gaap	Utilities Costs UtilitiesCosts	147887	USD
CY2017Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	814366	USD
CY2016Q1	us-gaap	Utilities Costs UtilitiesCosts	146107	USD
CY2017Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	614	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3217823	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	13915	USD
CY2016Q1	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	682590	USD
CY2017Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16130228	USD
CY2017Q1	us-gaap	Supplies Expense SuppliesExpense	119302	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1132423	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16222992	USD
CY2016Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	43921	USD
CY2017Q1	us-gaap	Liabilities Liabilities	20944065	USD
CY2016Q4	us-gaap	Liabilities Liabilities	20015736	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	13915	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1132423	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	289939	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	7385543	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-767642	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-786055	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	7764239	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	5052519	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13321471	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11686854	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34265536	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31702590	USD
CY2017Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	65473	USD
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	64967	USD
CY2016Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2482956	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	343818	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	4408631	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1106181	USD
CY2017Q1	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	558302	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.0676
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	18413	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1634617	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1591693	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1269	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	940301	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1361438	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-28360	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-21262	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	864	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	1587844	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	30496	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2930	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	441535	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	970797	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.0799
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	476353	USD
CY2017Q1	us-gaap	Interest Expense Other InterestExpenseOther	289939	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	1111491	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1412332	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	504713	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1129904	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	919	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	1360574	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	420273	USD
CY2017Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3919119	USD
CY2016Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3048462	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2528075	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1360169	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1588763	USD
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25	pure
CY2017Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3369665	USD
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3359619	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24307	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24119	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25521829	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2568047	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2247649	USD
CY2017Q1	jrss	Consulting Fee ConsultingFee	16373	USD
CY2016Q1	jrss	Consulting Fee ConsultingFee	17246	USD
CY2017Q1	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	325817	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3917	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	61890	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	352153	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-645275	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-591799	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1183264	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	679359	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	539082	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-272425	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-101388	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2982	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-7620	USD
CY2017Q1	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	USD
CY2016Q1	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	1155	USD
CY2017Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-61978	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	25675	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	215967	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1354162	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	373129	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70573	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10793	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	665253	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	123340	USD
CY2017Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	108873	USD
CY2016Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-83095	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	414043	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	919	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	864	USD
CY2017Q1	us-gaap	Interest Paid Net InterestPaidNet	289939	USD
CY2016Q1	us-gaap	Interest Paid Net InterestPaidNet	352406	USD
CY2017Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	2591155	USD
CY2016Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	81600	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	406934	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	437694	USD
CY2016Q1	us-gaap	Interest Expense Other InterestExpenseOther	343818	USD
CY2017Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	218670	USD
CY2016Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	1112691	USD
CY2012Q4	jrss	Joint Venture Investment Obligation To Pay Capital JointVentureInvestmentObligationToPayCapital	5555556	USD
CY2013Q2	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.7	pure
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26530624	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	1679089	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	1485427	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	13184695	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	18330749	USD
CY2017Q1	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	1981538	USD
CY2016Q1	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	343479	USD
CY2017Q1	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0609	pure
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	5701	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1111491	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	940301	USD
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	JRSIS HEALTH CARE Corp
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001597892
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Trading Symbol TradingSymbol	JRSS
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13915000	shares
CY2017Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	420829	USD
CY2016Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2017Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	262946	USD
CY2016Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
CY2017Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD
CY2016	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
CY2017Q1	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	69909	USD
CY2016Q1	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	502048	USD
CY2012Q4	jrss	Joint Venture Investment Obligation To Pay Capital JointVentureInvestmentObligationToPayCapital	35000000	CNY
CY2016Q4	jrss	Prepaid Maintenance Cost PrepaidMaintenanceCost	10000000	CNY
CY2016Q4	jrss	Prepaid Maintenance Cost PrepaidMaintenanceCost	1451136	USD
CY2017Q1	us-gaap	Prepaid Rent PrepaidRent	7000000	CNY
CY2017Q1	us-gaap	Prepaid Rent PrepaidRent	1015795	USD
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>C.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Use of estimates</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> <i>E.</i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt" align="justify"><i>Concentration of Credit Risk</i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the three months ended March 31, 2017 and 2016, no customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net revenue. As of March 31, 2017 and December 31, 2016, 3 and 2 customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-17-027058-index-headers.html	Edgar Link	pending
0001144204-17-027058-index.html	Edgar Link	pending
0001144204-17-027058.txt	Edgar Link	pending
0001144204-17-027058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jrss-20170331.xml	Edgar Link	completed
jrss-20170331.xsd	Edgar Link	pending
jrss-20170331_cal.xml	Edgar Link	unprocessable
jrss-20170331_def.xml	Edgar Link	unprocessable
jrss-20170331_lab.xml	Edgar Link	unprocessable
jrss-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466607_10q.htm	Edgar Link	pending
v466607_ex31-1.htm	Edgar Link	pending
v466607_ex31-2.htm	Edgar Link	pending
v466607_ex32-1.htm	Edgar Link	pending
v466607_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

2017 Q2 Form 10-Q Financial Statement

#000114420417027058 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS JRSIS HEALTH CARE Corp Stock $jrss

2017 Q2 Form 10-Q Financial Statement

#000114420417027058 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss